|
|
Academic Technology Transfer
Since the enactment of the Bayh-Dole Act, which opened the door to the proliferation of government-funded inventions, technology transfer has become an increasingly important function for academic institutions to enable the development and commercialization of emerging technologies.
Perkins Coie has worked with numerous technology transfer offices in assessing patentability, preparing and prosecuting patent applications and supervising foreign prosecution. These matters include cloning and the expression of recombinant genes, siRNA, small molecules, gene chips, real time multiplex PCR, genomics, proteomics, bioinformatics, data mining and clustering, anti-sense, gene therapy, drug delivery systems, cancer diagnostics, therapeutics and vaccines, microfluidic devices, nanotechnology, rational drug design, immuno-assays, recombinant vaccines, pharmaceuticals and bio-mechanical devices.
Our team understands the unique needs of academic institutions. Because we are actively involved in life sciences trade organizations and the investment community, we are able to identify and assess efficiently both the patentability and the commercial relevance of new technology. We regularly make presentations to our academic clients so that they can educate their scientists regarding the technology transfer process and the patent issues that frequently arise in an academic setting. These presentations include the distinctions between inventorship and authorship, the perils of publication and the necessity of documenting inventive activities.
|
 |
|